Ginsenoside Rh3 mitigates cisplatin-induced acute kidney injury with involvement of JAK2/STAT3 signaling
Frontiers in Pharmacology · 18.11.2026 · 17
DOI: 10.3389/fphar.2026.2013484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.11.2026. Verfasst von Liangchen Qu und 7 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cisplatin-induced acute kidney injury (AKI) is a major complication of chemotherapy, and effective protective strategies remain limited. This study aimed to investigate the renoprotective effects of ginsenoside Rh3 and explore the potential involvement of JAK2/STAT3 signaling in its protective mechanisms. First, network pharmacology, protein–protein interaction analysis, molecular docking, and molecular dynamics simulations were performed to identify potential targets and signaling pathways associated with Rh3. Subsequently, the protective effects of Rh3 were evaluated in a mouse model of cisplatin-induced AKI and in cisplatin-treated HK-2 cells. Cellular thermal shift assay (CETSA) and JAK2 overexpression experiments were further conducted to investigate the involvement of JAK2-associated signaling. Rh3 treatment alleviated cisplatin-induced renal dysfunction and histopathological damage in mice, as evidenced by improvements in serum creatinine, blood urea nitrogen, and renal injury markers. In HK-2 cells, Rh3 improved cell viability and reduced cell death, intracellular reactive oxygen species (ROS) accumulation, and apoptosis-associated protein expression. Furthermore, Rh3 improved oxidative stress-related indicators, including glutathione (GSH), superoxide dismutase (SOD), and malondialdehyde (MDA), and reduced the mRNA expression of interleukin-1β (IL-1β) and interleukin-6 (IL-6). Network pharmacology and molecular docking analyses identified JAK2 as a potential candidate target. CETSA demonstrated increased thermal stability of JAK2 following Rh3 treatment, while JAK2 overexpression partially reversed the protective effects of Rh3 on cell viability, ROS accumulation, and inflammatory marker expression. Rh3 treatment was also associated with reduced phosphorylation of JAK2 and STAT3. Collectively, these findings demonstrate the protective effects of ginsenoside Rh3 against cisplatin-induced AKI and suggest that modulation of JAK2/STAT3-associated signaling may contribute to its renoprotective effects.
Zitieren
APA
Qu, L., Cao, S., Zheng, X., Chen, T., Guo, Y., Feng, Q., Zheng, L., & Zhu, H. (2026). Ginsenoside Rh3 mitigates cisplatin-induced acute kidney injury with involvement of JAK2/STAT3 signaling. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2013484
Vancouver
Qu L, Cao S, Zheng X, Chen T, Guo Y, Feng Q, et al. Ginsenoside Rh3 mitigates cisplatin-induced acute kidney injury with involvement of JAK2/STAT3 signaling. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2013484
BibTeX
@article{Qu2026,
author = {Qu, Liangchen and Cao, Siqi and Zheng, Xiangqiong and Chen, Tingting and Guo, Yangyang and Feng, Qiaoyan and Zheng, Linghui and Zhu, Hengyue},
title = {Ginsenoside Rh3 mitigates cisplatin-induced acute kidney injury with involvement of JAK2/STAT3 signaling},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.2013484}
}
EUVIMED